Press Release

     View printer-friendly version
    << Back
    Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting
    - Blueprint Medicines to Host Investor Event and Webcast on June 5, 2017 -

    CAMBRIDGE, Mass., May 17, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, today announced that new data from its ongoing Phase 1 clinical trial evaluating BLU-285 for the treatment of advanced gastrointestinal stromal tumors (GIST) will be presented in an oral presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017.


    Presentation Title: Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST)
    Session Title: GIST: Imatinib and Beyond
    Date & Time: Monday, June 5, 2017 from 2:03-2:15 p.m. CT (3:03-3:15 p.m. ET)
    Abstract Number: 11011
    Location: E450ab (McCormick Place)

    The accepted abstract is available online on ASCO's website at

    Investor Event and Webcast Information

    Blueprint Medicines will host an investor event on Monday, June 5, 2017 beginning at 6:00 p.m. CT (7:00 p.m. ET) in Chicago to review the updated clinical data presented at ASCO for BLU-285 in GIST. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors section of the Company's website at A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.

    About Blueprint Medicines

    Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit

    To view the original version on PR Newswire, visit:

    SOURCE Blueprint Medicines

    Investor Relations: Kristin Hodous, Blueprint Medicines Corporation, 617-714-6674,; Media Relations: Rachel Hutman, W20 Group, 301-801-5540,

    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet